Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Yaning Wang, PhD
Advertisement
CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics
Articles by Yaning Wang, PhD
Applied Clinical Trials
Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Advertisement
Latest Updated Articles
PK in Late Phase TrialsFebruary 1st 2012
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
A Shot in the Arm to Traditional Vaccine Trial Strategy
5